Peenisathirku chooranam(internal)for Surapeenisam(Sinusitis in children)

Phase II Non-randomized clinical study on Surapeenisam (Sinusitis ) with the evaluation of the siddha trial drug Peenisathirkku chooranam (Internal) in children - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070139

Enrollment

Registered

2024-07-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J019- Acute sinusitis, unspecified

Interventions

Intervention1: Kandangkathari chooranam(internal): Kandangkathari chooranam 1-1.5 mg twice a day for 48 days internal therapy Intervention2: Peenisathirku chooranam (internal): Peenisathirku chooranam

Eligibility

Inclusion criteria

Inclusion criteria: Nasal congestion Running nose Headeache Heaviness of head Pain and tenderness over PNS Recurrent sneezing

Exclusion criteria

Exclusion criteria: Vasomotor rhinitis Ophthalmic headache Migraine Ottitis media Epistaxis

Design outcomes

Primary

Measure	Time frame
It is mainly assessed by reduction in clinical symptoms like nasal obstruction Reduction in visual analog scaleTimepoint: 14 days	—

Secondary

Measure	Time frame
Secondary outcome is assessed by reduction in ESR and eosinophil count Xray for paranasal sinuses It is assessed by comparing the safety parameters before and after treatmentTimepoint: 14 days	—

Countries

India

Contacts

Public ContactDr T Punitha

Goverment Siddha Medical College Arumbakkam Chennai

cspriya2004@gmail.com9445661808

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026